Myelodysplastic Syndromes Classification and Risk Stratification

被引:37
|
作者
Komrokji, Rami S. [1 ]
Zhang, Ling [1 ]
Bennett, John M. [2 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Univ Rochester, Strong Mem Hosp, James P Wilmot Canc Ctr, Rochester, NY 14642 USA
关键词
FAB; World Health Organization; IPSS; Myelodysplastic syndromes; WORLD-HEALTH-ORGANIZATION; FRENCH-AMERICAN-BRITISH; BONE-MARROW; MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA; SCORING SYSTEM; PROPOSALS; SURVIVAL; ANEMIA; PROGNOSIS;
D O I
10.1016/j.hoc.2010.02.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myelodysplastic syndromes (MDS) are spectrum of bone marrow failure disorders that share a common pathologic feature: cytologic dysplasia. The classification of MDS reflects the understanding of the disease. It is hoped that in the future classification and risk stratification will be based on underlying pathobiology of different disease subsets and molecular signatures where the pathologic classification represents their phenotype. This article reviews MDS classification and risk stratification highlighting differences between the various systems.
引用
收藏
页码:443 / +
页数:16
相关论文
共 50 条
  • [1] Updates in Risk Stratification in Myelodysplastic Syndromes
    Aguirre, Luis E.
    Sallman, David A.
    Stone, Richard
    Komrokji, Rami S.
    CANCER JOURNAL, 2023, 29 (03): : 138 - 142
  • [2] Risk Stratification of Myelodysplastic Syndromes - Is There Room for Improvement?
    Marques, Barbara Almeida
    Silva, Duarte Pacheco
    Santos, Joao Gaiao
    Moura, Pedro Pinho
    Ana Teresa Simoes, Catia Almeida
    Oliveira, Ana Catarina
    Coucelo, Margarida
    Cortesao, Emilia
    Geraldes, Catarina
    BLOOD, 2022, 140 : 12319 - 12320
  • [3] Editorial: Risk-stratification in myelodysplastic syndromes
    Breccia, Massimo
    Vinchi, Francesca
    Bonifacio, Massimiliano
    Binotto, Gianni
    Zheng, Gang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Cytogenetic Risk Stratification in Myelodysplastic Syndromes: Are We There Yet?
    Pardanani, Animesh
    Tefferi, Ayalew
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2703 - 2704
  • [5] Current state of prognostication and risk stratification in myelodysplastic syndromes
    Zeidan, Amer M.
    Gore, Steven D.
    Padron, Eric
    Komrokji, Rami S.
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (02) : 146 - 154
  • [6] The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes
    DeZern, Amy E.
    Greenberg, Peter L.
    BLOOD, 2023, 142 (26) : 2258 - 2267
  • [7] Epigenetic Biomarkers Are Applicable for Risk Stratification in Myelodysplastic Syndromes
    Mies, Anna
    Bozic, Tanja
    Kramer, Michael
    Franzen, Julia
    Ehninger, Gerhard
    Bornhauser, Martin
    Platzbecker, Uwe
    Wagner, Wolfgang
    BLOOD, 2016, 128 (22)
  • [8] Risk stratification in therapy-related myelodysplastic syndromes
    Zeidan, Amer M.
    ONCOTARGET, 2017, 8 (46) : 80103 - 80104
  • [9] Myelodysplastic Syndromes/Neoplasms-Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments
    Rose, Michal G.
    Zeidan, Amer M.
    CANCER JOURNAL, 2023, 29 (03): : 109 - 110
  • [10] Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes
    Cazzola, Mario
    Malcovati, Luca
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 459 - +